(related to Fig. 1 ). RBM24 is essential for cardiac development and required for sarcomerogenesis. (A) Targeting strategy for RBM24 alleles. The first exon was replaced by an IRES-rtTA expression cassette. Neomycin-resistance cassette (neo R ), the Frt sites (black triangles), Diptheria Toxin A (DTA) cassette, EcoRI restriction sites and probe (green bars) for southern blot analysis are indicated. (B) Southern blot analysis using genomic DNA isolated from E13.5 embryos with indicated genotypes. (C) Hematoxylin and eosin (H&E) staining of E10.5-E13.5 heart paraffin sections. Green arrows indicate reduced trabeculation. Bar = 10 μm. (D) Electron microscopy analysis of E12.5 hearts. Red arrows indicate Z-discs. Bar = 5 μm. (A) The RBM24OE allele efficiently expresses RBM24-EGFP in the heart after Cre recombinase-mediated activation via XMLC2v-Cre. The activity of the RBM24OE allele was tested by breeding RBM24OE mice with the XMLC2v-Cre strain expressing Cre recombinase specifically in the myocardium. Western blot analysis of RBM24 was performed using proteins RNA pull-down assays of RBM24-His recombinant protein using biotinylated RNA probes containing cluster 1. RBM24-His was detected by western blot analysis using an RBM24 antibody.
Figure S4 (related to Figs. 4-7). Analysis of the association of identified cis-regulatory sequences and RBM24-dependent exons. (A)
The presence of proximal GU stretches downstream of alternative exons and PTB and hnRNP A1/A2 binding sites in regions flanking upstream intron/alternative exon borders correlates with RBM24-dependent splicing. Constitutive exons upstream and downstream of RBM24-dependent exons were used as controls. The y-axis represents absolute scores. The boxes are drawn from 25% to 75% percentiles, and the whiskers are drawn from 5% to 95% percentiles. The median score (black line within the box) for RBM24-dependent exons is higher than that for the upstream or downstream constitutive exons indicating linkage between identified cis-regulatory sequences and RBM24-dependent exons. (B) Sequence of the exonic splicing silencer (ESS) located in exon 2. Nucleotide sequence of the 5'-part of exon 2 (E2-1). PTB and hnRNPA1/A2 binding sites are labeled in red and purple, respectively. Blue line labels the whole ESS. Red and black lines indicate 5' and 3' half of the ESS, respectively. Legend for table S1 (supplied as separate excel file, related to Figure 1, 2) . RBM24-dependent splicing events identified by RNA-Seq using E11.5 RBM24 WT and mutant hearts. The Excel table lists single exon inclusions, double exon inclusions, single exon exclusions and mutually exclusive alternative splicing events identified by RNA-Seq to depend on RBM24 in hearts of E11.5 mouse embryos. All values [junction-read-count: total number of sequence reads spanning a spliced junction; exon-read-density: total read-count in all positions of an exon per exon-length (for details, see (Rosel et al., 2011) ] given here are normalized by the total unique-read-count of the 6 samples (wildtype: WT-1, WT-2, WT3; mutant: MU-1, MU-2, MU-3). The corresponding positions of each junction-read-count and exon-density are indicated in the schematic alternative splicing pattern (number in round-bracket for junction-count, in square-bracket for exon-density). Table S1 ). The enrichment scores for each individual exon were obtained by using an algorithm integrating positional information of splicing activators and silencers.
Supplementary Experimental Procedures Animals
The RBM24 constitutive knockout allele was generated by replacing exon 1 with an IRES-rtTA expression cassette followed by a Frt-flanked neomycin-resistance gene (neo R ) cassette in V6.5 F1 hybrid embryonic stem cells ( Figure S1A ). Targeted stem cell clones were selected by G418
and screened by Southern blotting. Positive clones were injected into C57BL/6 (B6) blastocysts.
The resultant chimeric mice were mated to Flp-expressing transgenic mice to generate neocassette deleted heterozygous mice (RBM24+/-), which were subsequently mated to wild-type C57BL/6 mice. Heterozygous mice were crossed to obtain homozygous embryos for analysis.
Genotyping was done by PCR using primers CTGCGCAAGTACTTTGAGGTCTTCG (forward for wild-type allele), TTCAGCT TAGCTCCGAGTGAACGG (reverse for wild-type allele), ATCCCACTAAGCCACTCGAT (forward for mutant allele) and CATTCAACAGACCTTGCATTCC (reverse for mutant allele). The RBM24OE allele was generated by using a generic ROSA26 targeting system as described previously (Srinivas et al., 2001 ). RBM24 cDNA was amplified from RNAs extracted from embryonic hearts and cloned into pEGFP-N3 using XhoI and KpnI. RBM24-EGFP was then released using NheI and NotI, and subcloned into the pBigT vector, which contains a neo cassette and a strong transcriptional termination sequence (tpA) flanked by loxP sites. pBigT was then digested with PacI and AscI to release the entire floxed neo-tpA and RBM24-EGFP assembly, which was subsequently inserted into pROSA26PA containing ROSA26 genomic arms for homologous recombination in embryonic stem cells. Mice carrying the targeted allele were genotyped by PCR as described (Soriano, 1999) .
Morphological analysis
Mice were sacrificed by cervical dislocation before embryos, adult hearts and skeletal muscles were isolated and fixed with 4% paraformaldehyde for paraffin section and H&E (hematoxylin and eosin) staining or with 3% glutaraldehyde for electron microscopy analysis. For analysis of the embryonic cardiac phenotype at least 4 mutant and 5 wild-type embryos from each time point were used. For adult heart and skeletal muscle analysis, at least 3 mutant and 3 control animals were used.
RT-PCR and Real-time PCR analysis
RT-PCR was used to validate potential candidate exons. Total RNA was isolated using TRIzol reagent (Invitrogen), followed by cDNA synthesis using Oligo(dT) primers and Superscript II reverse transcriptase (Invitrogen). 25-30 cycles for PCR were used routinely. Identities of all PCR products were confirmed by sequencing using the primers listed below. Exon inclusion efficiency was calculated by dividing the amount of muscle-specific product by the sum of all PCR products. Total RNAs from human tissues were purchased from BioChain. Brain (catalog # R1234035-50, lot# B304106), heart (catalog #R1234122-50), lung (catalog # R1234152-50, lot#B307203) and skeletal muscle (catalog # R1234171-50, lot#B207204).
Quantification of exon inclusion efficiencies for Naca and Slc25a3 was achieved by real-time PCR. RNAs from 3 WT and 3 mutant hearts (E11.5) were used. Each sample was assayed in triplicates. The 2 -ΔΔCt method was used to calculate relative expression of muscle-specific exons by normalizing to the expression level of constitutive exons within the same gene (Guo et al., 2012) . For Naca, Tagman assay was used according to manufacturer's instruction (Applied Biosystems). The following probes were used: Mm01702879_g1 (internal control), Mm01702880_gH (aNac), Mm00479007_m1 (skNac). For Slc25a3, ABsolute Blue QPCR SYBR Green Low ROX Mix (Thermo Fisher Scientific, Inc.) was used to prepare real-time PCR master mixes. Amplifications were done using an iCycler iQ qPCR machine (Bio-Rad). The following primers were used for Slc25a3: TTGGCTATTCCATGCAAGGG (internal control, forward), GAATTCAGCACTGGCAGAAG (internal control, reverse), ACACCTG CAGCTGGTGCACG (muscle isoform, forward), CAGAGGAGAAAGAATCTGCC (muscle isoform, reverse), ACACCTGCAGCTGGTGCACG (general isoform, forward), AGCCACA CAGTGCATAATAC (general isoform, reverse).
Construction of splicing reporters
The splicing reporter SR1-3, which recapitulates splicing of the Naca genomic locus, encompasses the region from exon 1 to exon 3. Intron 1 and exon 2 were shortened internally.
SR1-3 was assembled from 4 fragement, which were amplified by PCR using mouse tail genomic DNA and cloned into N3EGFP using the following restriction sites: EcoRI/SpeI for fragment 1, SpeI/EcoRV for fragment 2, EcoRV/Sal for fragment 3, and SalI/BamHI for fragment 4. PacI and AscI were introduced upstream of fragment 1 and downstream of fragment 4, respectively. The 4 fragements were then released as a whole assembly by PacI and AscI and subcloned into a modified pCAGIPuro vector, which contains the hybrid CMV immediate early enhancer/β-actin (CAG) promoter.
The SR4-6 splicing reporter was generated using sequences from the Naca genomic locus including exon 4 to exon 6. Four genomic fragments were amplified and introduced into pCAGIPuro following the same strategy as for SR1-3.
HeLa cell splicing assays
Splicing reporters were transfected together with different expression vectors into HeLa cells using Lipofectamine 2000 (Invitrogen) according to manufacturer's instruction. After 24 hours, total RNA was isolated using TRIzol reagent and reverse-transcribed using random primer and superscript II (Invitrogen). The following primers were used: CCCGGTGAAGCC ACAGAAAC (SR1 Forward), GAGTCTTGTTCCTCGAGCTC (SR1 reverse), CGCAGCAG AGATCGATGAAG (E4-6 Forward), CTCCTCTTCTTCACTCTCCTC (E4-6 reverse). Identities of all PCR products were confirmed by sequencing.
Purification of RBM24-His recombinant protein
RBM24 full length cDNA was amplified from total RNA isolated from embryonic hearts and cloned into pET-26b(+) vector ( 
HeLa nuclear extract in vitro splicing assays
In vitro splicing assays were performed as described previously (Mayeda and Krainer, 1999) .
HeLa cell nuclear extracts were purchased from Jena Bioscience (PR-778) and Ipracell (CC-01-20-50). Pre-mRNA probe was in vitro transcribed using the TranscriptAid T7 High Yield Transcription Kit (K0441, Thermo Scientific) and the SR1-3 splicing reporter as template. m7G
Cap Analog (P1711, Promega) was included in the in vitro transcription reaction to produce capped RNA probe and increase splicing efficiency. Each in vitro splicing reaction contained 1μl of 25X ATP/CP (1.25mM ATP, 0.5M creatine phosphate), 1μl of 80mM MgCl 2 , 1.25μl of 0.4 M HEPES-KOH (pH7.3), 5μl of 13% PVA (polyvinyl alcohol), 500ng RNA probe (0.5μl), 5μl
RBM24-His protein (300ng), and 13μl nuclear extract (pre-incubated at 30 degree for 10min). In each experiment, ATP-free reactions were used as negative controls. The reaction mixture was then incubated at 30°C for 4 hours. After incubation, 97μl proteinase K buffer (50mM Tris-HCL, pH 7.4, 150mM NaCl, 1mM MgCl 2 , 0.05% NP40), 15μl of 10% SDS, and 18μl of 10mg/ml proteinase K were added to the mixture, which was then incubated at 55 °C with shaking for 20min. RNAs were purified using the RNA Clean & Concentrator (R1015, ZYMO research) after cooling the reactions to room temperature. Purified RNA was subjected to reverse transcription using random primers. RT-PCR was performed to analyze the inclusion efficiency of alternative exons.
Biotin-RNA pull-down assays
Biotin-RNA pull-downs were performed as described previously (Anyanful et al., 2004 ) using a 120bp template amplified from the splicing reporter SR1-3. The template contained the 3' part of E2-2 and the 5' part of the downstream intron harboring cluster 2. GU stretches within cluster 2 were mutated changing T to C or G to C. Biotinylated WT and mutant RNA probes were transcribed in vitro using T7 RNA polymerase (Promega) and Biotin RNA Labeling Mix (Roche Applied Science) followed by DNase I (Promega) treatment to remove templates. RNA probes were purified using the RNA Clean & Concentrator (R1015, ZYMO research). Biotin-labeled RNA at 0.1 μM was incubated with purified RBM24-His in RP buffer (50 mM KCl, 1 mM MgCl2, 10 mM Hepes-NaOH, pH 7.5) containing 5μl of 10mg/ml tRNA (Ambion), 5μl of 100 X Protease inhibitor(Roche) and 5 μl of RNasin Ribonuclease Inhibitor (Promega) in a final volume of 500 μl at RT for 30 min. Mixtures were incubated with 0.1 mg of streptavidin MagneSphere
Paramagnetic beads (Promega) at RT for 20 min. After washing of the beads five times with RP buffer, bound proteins were released by boiling beads in SDS sample buffer at 95°C for 5 min.
Western blotting was used to analyze the bound proteins using anti-RBM24 antibodies. The score was assembled from two parts. The first part assessed the repressive signals (factors A1/A2 and PTB) in the alternative exons. The second part assessed the occurrence and the position of the RBM24 binding sites and the co-localization of Fox1 sites. By multiplying these two parts, the score accounted for the necessity of having a repressive signal in the exon as well as an activating signal for RBM24 in the 3' intron. Sequences lacking one of the putative signals were multiplied with 0.
All positions
were assumed to have a higher impact when located close to either the 5' or 3' exon border, respectively. Therefore, the quotient of relative positions contributes linearly to the score. For the first part of the score, we assumed a stronger repressive signal for multiple A1 or PTB binding sites. Representation of binding sites was taken into account by summing up all positions. In case of posRBM24, the first motif in the 3' intron was used. The distRBM24-FOX1 value to posRBM24 was calculated for all occurring motif combinations. Only the best performing pair of RBM24 and FOX1 was chosen. The factor was squared to primarily score FOX1 motifs located close to the RBM24 binding site
The weights of the scoring function were trained by applying to validated gene sets. A score list for each candidate was generated independently. The weights k, I, x and y were alternated in 0.1 steps, whereas the total sum of weights had to be one. The best scoring weight set for was chosen.
A final trained weight set was obtained by calculating the average on each weight position.
PCR Primers

